Welcome to our dedicated page for Bodhi Tree Biotechnology SEC filings (Ticker: BDTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bodhi Tree Biotechnology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bodhi Tree Biotechnology's regulatory disclosures and financial reporting.
Bodhi Tree Biotechnology Inc. reported a net loss of $52,948 for the three months ended December 31, 2025, compared with a $64,777 loss a year earlier. The company generated no revenue in the quarter, versus $5,000 in the prior-year period, as it builds its vegetarian menu and diet consulting business.
Cash declined to $47,366 from $109,404 at September 30, 2025, with total assets of $69,713 and stockholders’ equity of $66,213. Accumulated deficit reached $264,567, and operations were funded entirely by existing capital.
Management disclosed material weaknesses in internal control over financial reporting, citing limited U.S. GAAP expertise and insufficient segregation of duties. During the quarter, the company’s application to have its common stock quoted on the OTCQB Venture Market was approved, and certain share legends were removed to increase public float.
Bodhi Tree Biotechnology Inc., an early-stage vegetarian menu design and diet consulting company based in Danville, California, reported a small consulting business with limited operations in its annual report for the year ended September 30, 2025. Service revenue was $17,000, down from $35,000 for the prior period from inception to September 30, 2024, while general and administrative expenses rose to $164,618. The company recorded a net loss of $149,666 versus $61,953 previously, reflecting professional and overhead costs outpacing revenue.
As of September 30, 2025, Bodhi Tree held $109,404 in cash, total assets of $119,161, no liabilities, and stockholders’ equity of $119,161. There were 25,441,042 common shares outstanding as of both September 30 and December 29, 2025. The business has no full-time employees beyond executives, subleases a small office for $900 per month, owns two U.S. trademarks, and highlights numerous risks including limited operating history, dependence on key management, financing needs, competition, thin trading and penny-stock constraints.